Evidence map›Paper›PMID 31384747›Full record

ArticleVaccine: X2019

Evaluating the cost per child vaccinated with full versus fractional-dose inactivated poliovirus vaccine.

Mercy Mvundura, Jui-Shan Hsu, Collrane Frivold, Debra Kristensen, Shanda Boyle, Darin Zehrung, Courtney Jarrahian

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine: X, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Potential Future Use, Costs, and Value of Poliovirus Vaccines.Risk analysis : an official publication of the Society for Risk Analysis · 2021
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mercy MvunduraPATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA.
Jui-Shan HsuPATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA.
Collrane FrivoldPATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA.
Debra KristensenPATH, Rue de Varembé 7, 1202 Geneva, Switzerland.
Shanda BoyleBill & Melinda Gates Foundation, 500 Fifth Avenue North, Seattle, WA 98109, USA.
Darin ZehrungPATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA.
Courtney JarrahianPATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA.
Program for Appropriate Technology in Health · USGates Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionInactivated poliovirus vaccine (IPV) shortages and evidence of improved immunogenicity of two intradermal (ID) fractional IPV (fIPV) doses compared with one full intramuscular dose led to recommendations for fIPV delivery. To provide evidence on the economics of fIPV, we estimated the cost per child vaccinated using full-dose IPV compared with fIPV in routine and campaign settings. We evaluated the impact on costs of alternative devices facilitating ID administration, vaccine vial sizes, and prices.

methodsWe used an Excel-based model to estimate the commodity and delivery costs for providing IPV. Commodity costs included vaccine price per dose adjusted for wastage, prices for vaccine administration devices, and safety boxes. Delivery costs included storage costs at each level of the supply chain, transport costs for commodities between levels, and human resource costs for vaccine administration. Model inputs were obtained from various databases and published literature. All costs are reported in 2018 US dollars.

resultsIn both campaign and routine settings, fIPV had a lower cost per child vaccinated than full dosing, despite the assumed higher vaccine wastage with fIPV in routine settings, and even when novel ID administration devices were used. In routine settings, costs per child fully vaccinated with fractional doses were 15% to 48% lower than those with full-dose delivery across different vial sizes. The cost per child vaccinated ranged from $1.84 to $2.65 for fractional doses, depending on the administration device, compared with $3.57 for full dose, when using 5-dose vials. The magnitude of cost reductions with fIPV relative to full-dose IPV was largest with smaller vial sizes and higher vaccine price.

conclusionAdopting fIPV can reduce costs per child vaccinated compared with using full doses, especially as IPV prices increase in the short term and more so when two full doses could be recommended in the future.

Indexed as

AD, autodisableBCG, bacillus Calmette-GuérinbOPV, bivalent oral poliovirus vaccinecMYP, comprehensive multiyear plan for immunizationCostingCost per childfIPV, fractional-dose inactivated poliovirus vaccineFractional doseFractional IPVID, intradermalIM fIPV, intramuscular administration of fractional doses of IPVIM, intramuscularImmunizationInactivated poliovirus vaccineIPV, inactivated poliovirus vaccineN&S, needle and syringeOPV, oral poliovirus vaccineSAGE, strategic advisory group of expertstOPV, trivalent oral poliovirus vaccineUNICEF, United Nations Children’s FundUS$, US dollarsVDPV, vaccine-derived poliovirusWHO, World Health Organization

Identifiers

PMID31384747
PMCPMC6668218
OpenAlexW2961772612

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.